Observational studyJournal of Korean medical science2023
Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study.
Observational study in Journal of Korean medical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Pooled it
- Efficacy and Safety of Nirmatrelvir/Ritonavir and Molnupiravir in Non-Hospitalized Patients with COVID-19: A Single-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2026Article
- Patient Characteristics and Healthcare Resource Use among Patients With COVID-19 Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID™) in the Kingdom of Saudi Arabia.Pulmonary therapy · 2026Article
- Cardiovascular Risks of COVID-19 Therapeutics: Integrated Analysis of FAERS, Electronic Health Records, and Transcriptomics.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study.Frontiers in cellular and infection microbiology · 2026Observational
- Post-marketing surveillance study on the effectiveness and safety of molnupiravir in high-risk COVID-19 outpatients: a prospective case series study.Pharmacological reports : PR · 2025Article
- Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data.Biomedicines · 2025Article
- Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms.Acta pharmacologica Sinica · 2025Review
- Patient-Reported Adverse Events Among Elderly Patients Receiving Novel Oral COVID-19 Antivirals: A Nationwide Sampled Survey in Korea.Journal of Korean medical science · 2024Article
- Article
- Could Molnupiravir Be the First-Line Alternative Oral Antiviral Agent for COVID-19 Patients at High Risk?Journal of Korean medical science · 2024Article
- Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.Journal of Korean medical science · 2024Article
- Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study.Frontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundIn this study, we aimed to compare the effectiveness and adverse reactions of nirmatrelvir/ritonavir and molnupiravir in high-risk outpatients with coronavirus disease 2019 (COVID-19).
methodsThis multicenter prospective observational study evaluated the rate of hospitalization, death, and adverse events within 28 days of oral antiviral agent prescription (molnupiravir, n = 240; nirmatrelvir/ritonavir, n = 240) to 480 nonhospitalized adult patients with COVID-19 from August 2, 2022 to March 31, 2023.
resultsPatients receiving molnupiravir had a higher prevalence of comorbidities (85.8% vs. 70.4%;
conclusionThe rates of hospitalization and death were low and not significantly different between high-risk patients who received either nirmatrelvir/ritonavir or molnupiravir. Although adverse events were more frequent with nirmatrelvir/ritonavir than with molnupiravir, none were severe. Nirmatrelvir/ritonavir can be safely used to treat COVID-19, while molnupiravir could be considered as an alternative treatment option for high-risk groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.